GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Resonance Specialties Ltd (BOM:524218) » Definitions » Debt-to-EBITDA

Resonance Specialties (BOM:524218) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Resonance Specialties Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Resonance Specialties's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Resonance Specialties's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Resonance Specialties's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹62.9 Mil. Resonance Specialties's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Resonance Specialties's Debt-to-EBITDA or its related term are showing as below:

BOM:524218' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.87   Max: 2.23
Current: 0.51

During the past 13 years, the highest Debt-to-EBITDA Ratio of Resonance Specialties was 2.23. The lowest was 0.01. And the median was 0.87.

BOM:524218's Debt-to-EBITDA is ranked better than
79.72% of 1213 companies
in the Chemicals industry
Industry Median: 2.31 vs BOM:524218: 0.51

Resonance Specialties Debt-to-EBITDA Historical Data

The historical data trend for Resonance Specialties's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resonance Specialties Debt-to-EBITDA Chart

Resonance Specialties Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.05 0.01 0.27

Resonance Specialties Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.30 - 0.69 -

Competitive Comparison of Resonance Specialties's Debt-to-EBITDA

For the Chemicals subindustry, Resonance Specialties's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resonance Specialties's Debt-to-EBITDA Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Resonance Specialties's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Resonance Specialties's Debt-to-EBITDA falls into.



Resonance Specialties Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Resonance Specialties's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.131 + 19.757) / 83.605
=0.27

Resonance Specialties's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 62.904
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Resonance Specialties  (BOM:524218) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Resonance Specialties Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Resonance Specialties's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Resonance Specialties (BOM:524218) Business Description

Traded in Other Exchanges
N/A
Address
Plot No. 54-D, Kandivli Industrial Estate, Kandivli (West), Charkop, Mumbai, MH, IND, 400067
Resonance Specialties Ltd is engaged in the manufacturing of chemicals. The company is manufacturing Pyridine, Picoline, Cynopyridine, and derivatives of the same. Bulk drugs and nutritional products are tolls converted. It delivers pyridine and related products. The company has only one segment which is Chemical Manufacturing. The company also manufactures anti-tuberculosis products such as Isoniazid. Geographically. It operates in India and Outside India. The majority of segment revenue is from Outside India.

Resonance Specialties (BOM:524218) Headlines

No Headlines